The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma

Liu Wei; Chen Shengkai; Yang Wenbin

首页> 外文期刊>Oral oncology >The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma

【24h】

The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma

机译：关于头部鳞状细胞癌研究的PD-L1积极性和消极性的多样性截止

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oral oncology》 |2018年第2018期|共2页
作者
Liu Wei; Chen Shengkai; Yang Wenbin;
展开▼
作者单位

Sichuan Univ State Key Lab Oral Dis West China Hosp Stomatol Dept Head &

Neck Oncol 14 Sect;

Sichuan Univ State Key Lab Oral Dis West China Hosp Stomatol Chengdu Sichuan Peoples R China;

Sichuan Univ State Key Lab Oral Dis West China Hosp Stomatol Dept Head &

Neck Oncol 14 Sect;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类耳鼻咽喉科学;
关键词

相似文献

外文文献
中文文献
专利

1. The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma [J] . Liu Wei, Chen Shengkai, Yang Wenbin Oral oncology . 2018,第期

机译：关于头部鳞状细胞癌研究的PD-L1积极性和消极性的多样性截止
2. A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR [J] . Siu L., Even C., Mesia R., International Journal of Radiation Oncology, Biology, Physics . 2018,第5期

机译：Durvalumab（d），Tremetimumab（t），或d plus t的随机，开放标签，多中心，全局阶段2研究PD-L1低/负复发或转移性头部和颈鳞状细胞癌：CONDOR
3. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma [J] . Chung Christine H., Rudek Michelle A., Kang Hyunseok, Oral oncology . 2016,第Null期

机译：I期研究阿法替尼/卡铂/紫杉醇诱导化疗，然后在HPV阴性或高危HPV阳性局部晚期III / IVa / IVb头颈部鳞状细胞癌中进行标准化学放疗
4. Proteomics Study of Head-And-Neck Squamous Cell Carcinoma Using iTRAQ Labeling and an Iterative LC-MS Analysis [C] . Sebastien N. Voisin, Olga Krakovska, Ajay Matta, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：使用ITRAQ标记和迭代LC-MS分析的头颈鳞状细胞癌的蛋白质组学研究
5. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. [D] . 野﨑, 結 2019

机译：PD-L1特异性辅助性T细胞表现出有效的抗肿瘤反应：针对头颈部鳞状细胞癌中PD-L1的癌症免疫疗法的新策略。
6. A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing [O] . Anthony C. Nichols, Michelle Chan-Seng-Yue, John Yoo, 2012

机译：通过全外显子组测序比较HPV阳性和HPV阴性的头颈部鳞状细胞癌的先导研究
7. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25 tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy [O] . Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno, 2019

机译：杜威拉姆用于复发性或转移性头部和颈鳞状细胞癌：由≥25％肿瘤细胞PD-L1表达患者的单臂，II期研究结果，达到铂基化疗

The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma

著录项

相似文献

相关主题

期刊订阅